Method Article

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

1.9K views

⸱

DOI:

10.3791/65811

⸱

February 2nd, 2024

 ,  ,  ,  ,  ,  , 
1Centre for Regenerative Medicine, Institute of Regeneration and Repair, Institute of Stem Cell Research, The University of Edinburgh, 2King Abdulaziz City for Science and Technology Health Sector (KACST), 3Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, 4Brenden-Colson Canter for Pancreatic Care, Oregon Health & Science University, 5Department of Surgery, Oregon Health & Science University, 6Department of Molecular & Medical Genetics, Oregon Health & Science University

Corresponding Authors: Abdenour Soufi <Abdenour.Soufi@ed.ac.uk>

In This Article

Summary

The present protocol describes the reprogramming of Pancreatic Ductal Adenocarcinoma (PDAC) and normal pancreatic ductal epithelial cells into induced pluripotent stem cells (iPSCs). We provide an optimized and detailed, step-by-step procedure, from preparing lentivirus to establishing stable iPSC lines.

Abstract

The generation of induced pluripotent stem cells (iPSCs) using transcription factors has been achieved from almost any differentiated cell type and has proved highly valuable for research and clinical applications. Interestingly, iPSC reprogramming of cancer cells, such as pancreatic ductal adenocarcinoma (PDAC), has been shown to revert the invasive PDAC phenotype and override the cancer epigenome. The differentiation of PDAC-derived iPSCs can recapitulate PDAC progression from its early pancreatic intraepithelial neoplasia (PanIN) precursor, revealing the molecular and cellular changes that occur early during PDAC progression. Therefore, PDAC-derived iPSCs can be used to model the earliest stages of PDAC for the discovery of early-detection diagnostic markers. This is particularly important for PDAC patients, who are typically diagnosed at the late metastatic stages due to a lack of reliable biomarkers for the earlier PanIN stages. However, reprogramming cancer cell lines, including PDAC, into pluripotency remains challenging, labor-intensive, and highly variable between different lines. Here, we describe a more consistent protocol for generating iPSCs from various human PDAC cell lines using bicistronic lentiviral vectors. The resulting iPSC lines are stable, showing no dependence on the exogenous expression of reprogramming factors or inducible drugs. Overall, this protocol facilitates the generation of a wide range of PDAC-derived iPSCs, which is essential for discovering early biomarkers that are more specific and representative of PDAC cases.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies, and early diagnosis remains challenging due to the asymptomatic nature of the disease. The majority of PDAC patients are diagnosed at the advanced metastatic stage when very limited treatment options are available1,2. This is mainly due to the lack of reliable biomarkers for the earlier stages, such as those that could be conveniently detected as proteins released into the bloodstream.

PDAC can disseminate very early during its progression, and a better prognosis has been linked to early cancer detection when PDAC is localized in the pancreas3. However, less than a tenth of PDAC patients are diagnosed with a favorable prognosis, allowing for surgical resection. Nonetheless, those few with resectable tumors are also prone to tumor recurrence within 12 months4.

In the past five decades, remarkable improvements have been made in surgical techniques, patient care, and treatment modalities5,6. However, the 5-year survival rate in surgically resected PDAC patients has barely risen to 17%. Nonetheless, this is still better than that in non-resected patients, which has remained almost unchanged (0.9%)4,7. Chemotherapy is the only other alternative PDAC treatment. Yet, this option is very limited as the great majority of PDAC patients exhibit strong resistance to chemotherapy medications such as Gemcitabine7,8. Other drugs, such as Erlotinib, are only available to a small group of PDAC patients with specific mutations, most of whom show Erlotinib resistance9. The adverse side effects associated with chemotherapy in most PDAC patients are yet another disadvantage of this treatment10. Recently, promising strategies have shown that immune checkpoint inhibitors (ICIs) and small molecule kinase inhibitors (SMKIs) can be effective in treating PDAC, but durable responses to these targeted therapies remain limited to a minority of patients11,12. Overall, the discovery of PDAC-specific early biomarkers can pave new avenues for early diagnosis and treatment.

PDAC develops from pancreatic intraepithelial neoplasms (PanIN) precursor lesions that result from non-invasive pancreatic duct epithelial proliferations13,14. While the formation of PanIN is initiated by oncogene mutations such as KRAS, additional genetic and epigenetic alterations are required for the progression to PDAC. It has been projected that the progression of PanIN through the different stages into invasive PDAC takes about 10 years13,15,16,17. This timeframe provides a great opportunity to benefit from early PDAC diagnosis. Therefore, extensive research has been carried out to establish tumor xenograft animal models and organoid cultures to study PDAC progression18,19,20,21. These models have been very useful for studying the invasive stages of PDAC, although not the transition from the early PanIN phases. It is, therefore, important to develop experimental models that can recapitulate the early progression of PanIN stages to enable the discovery of early detection biomarkers.

Reprogramming somatic cells into induced pluripotent stem cells (iPSCs) using the four transcription factors OCT4, SOX2, KLF4, and c-MYC (OSKM) has illustrated the extent of cellular plasticity22. Cancer cell plasticity has been well-documented, and reprogramming human cancer cells into iPSCs has been successfully used to reset cells to their original cellular state, removing many of the epigenetic insults that have accumulated during cancer progression23,24,25,26,27,28,29. The possibility of using this reprogramming strategy to manipulate cancer cell identity has, therefore, presented great promise in treating cancer30,31. Indeed, we have previously shown that the differentiation of iPSCs derived from PDACs can recapitulate PDAC progression through the early PanIN stages32. By identifying genes and pathways specific to the early-to-intermediate stages of PDAC, candidate biomarkers were identified that can be clinically used for early PDAC diagnosis32,33. However, the biomarkers discovered using a single iPSC line showed limited coverage in the majority of PDAC patients32. The challenges of generating iPSC lines from other PDAC patients have halted the ability to discover more reliable biomarkers. This is due to many technical factors, including the heterogeneity of OSKM delivery, as only a small portion of human primary PDAC cells contained all four factors and responded successfully to reprogramming. Here, a detailed protocol is presented for reprogramming primary PDAC cells using a more efficient and consistent dual lentiviral delivery of OSKM.

Protocol

All experimental protocols were approved by the OHSU Institutional Review Board. All methods were carried out in accordance with relevant guidelines and regulations. All animal works for PDX tumors were performed with the OHSU Institutional Animal Use and Care Committee (IACUC) approval. This protocol was tested in Primary PDAC cells from patient-derived xenograft (PDX), BxPc3 cell line exhibiting epithelial morphology that was isolated from the pancreas tissue of a 61-year-old female patient with adenocarcinoma, the H6C7 immortalized epithelial cell line derived from normal human pancreatic duct epithelial, and primary human fibroblasts derived from skin biopsy of healthy individuals. Human PDAC specimens were obtained under the Oregon Pancreas Tissue Registry study (IRB00003609). Informed consent was obtained from all subjects. Human primary fibroblasts were derived in RBiomedical, Edinburgh, UK, from skin samples from anonymous donors undergoing routine surgery at the Edinburgh Royal Infirmary, Little France, UK, under their consent and ethical approval (09/MRE00/91).All lentivirus work has been carried out under Class 2 research activity (GM207/16.6) and approved by the Health and Safety Department at the University of Edinburgh and notified to the HSE competent authority of the Scottish Government. All reprogramming experiments using human pancreatic cells were carried out under the ethical approval of the School of Biological Sciences ethics committee at the University of Edinburgh (reference # asoufi-0002).

1. Preparation of lentiviruses

  1. For lentivirus preparation, prepare high-quality packaging and expression plasmids (endotoxin-free) with concentrations between 1-2 µg/µL including psPAX2, pMDG34, and two RES-containing bicistronic vectors; the pSIN4-EF1a-O2S encoding for OCT4 and SOX2 expression driven by EF-1α promoter, and pSIN4-CMV-K2M for KLF4 and c-MYC expression under the CMV enhancer/promoter35 (see Table of Materials). Also, prepare pWPT-GFP plasmid to be used as a transfection control.
  2. Thaw Human Embryonic Kidney cell line (293T) and culture in Glasgow's Minimum Essential Medium (GMEM), supplemented with 10% fetal calf serum (FCS), 1x non-essential amino acids, 1 mM sodium pyruvate and 1 mM glutamine at (see Table of Materials) 37 °C and 5% CO2.
    NOTE: It is recommended to use 293T cells within four passages post thawing.
  3. Seed 293T at a density of 3 million cells per 15 cm dish, 24 h before transfection. A total of three dishes are required. It is preferable to seed cells later in the afternoon ~16:00.
  4. Next day (~16:00), when cells reach ~40%-50% confluency, prepare the following for three transfection reactions:
    NOTE: Always account for pipetting error by adding 10% volume extra.
    1. Label three 15 mL plastic tubes with the appropriate lentivirus name (pSIN4-EF1a-O2S, pSIN4-CMV-K2M, and pwPT-GFP control). Add 1.710 mL reduced serum medium (see Table of Materials) to each tube.
    2. Dilute 90 µL transfection reagent (see Table of Materials) in 1.710 mL reduced serum medium, mix by vertexing for 2 s, and incubate at room temperature for 5 min.
    3. Mix the packaging vectors; 5.1 µg of psPAX2 and 2.4 µg of pMDG (7.5 µg total).
    4. Add the packaging vector mixture to the transfection medium (from step 1.4.2) and vortex for 2 s.
    5. Add 7.5 µg of each reprogramming vector: pSIN4-EF1a-O2S and pSIN4-CMV-K2M and the pwPT-GFP control to the transfection mixture from step (1.4.4) and vortex for 2 s.
      NOTE: Use the expression vector: viral vector at a 1:1 ratio.
  5. Incubate the transfection tubes for 15 min at room temperature.
  6. Transfect the 293T cells with each lentivirus by directly adding the transfection-DNA mixture from step (1.4.5) to the media in a dropwise fashion. Swirl the dish to ensure even distribution across the entire surface.
  7. Incubate the transfected cells in a 37 °C, 5% CO2 incubator overnight.
    NOTE: Use virus-specific waste, a metal disposal bucket, double bag with autoclave bags, and take a liquid waste container for virus and add a disinfectant tablet. Dispose of all pipettes, tips, and tubes in a metal bucket. Dispose of old media into a virus-liquid waste container. Avoid using glass pipettes and glassware to eliminate accidental virus contamination.
  8. After 14-16 h post-transfection, replace the medium with 30 mL fresh 293T medium.
  9. Incubate the transfected cells at 37 °C, 5% CO2 for 60-72 h post medium change. Observe cells daily and check transfection efficiency by GFP fluorescence.
    NOTE: Ideally, transfection efficiency should be >90% by GFP. For the other viruses, one should observe clear morphological changes of 293T cells, as they tend to become more round when producing virus particles.
  10. Collect the media from each virus transfection culture into 50 mL tubes and spin down to clear out cell debris at 1932 x g for 10 min at 4 °C.
  11. Filter each lentivirus supernatant through a 0.45 µM syringe filter to remove smaller debris and collect it into new 50 mL tubes.
  12. Divide each lentivirus supernatant into 6 mL aliquots and snap freeze each in liquid nitrogen.
  13. Store the lentivirus aliquots at -80 °C until ready to use.

2. Reprogramming lentivirus transduction

  1. Thaw primary PDAC cells and culture in completely defined Keratinocyte Serum Free Medium (KSFM), supplemented with Bovine Pituitary Extract (BPE), human recombinant Epidermal Growth Factor (EGF) at 5 ng/mL, and Cholera toxin at 50 ng/mL in a 37 °C, 5% CO2, and 5% O2 (hypoxia) incubator (see Table of Materials).
  2. Thaw BxPc3, a squamous pancreatic ductal adenocarcinoma cell line, and culture in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) at 37 °C, and 5% CO2.
  3. Thaw H6C7 cells, pancreatic ductal epithelial cells, and culture in KSFM supplemented with BPE and EGF at 5 ng/mL, at 37 °C and 5% CO2.
  4. Thaw Human fibroblast (hFib) and culture in Glasgow's Minimum Essential Medium (GMEM), supplemented with 10% FCS, 1x non-essential amino acids, 1 mM sodium pyruvate and 1 mM glutamine, and 0.05 mM (final) Beta-mercaptoethanol at 37 °C and 5% CO2.
  5. One day prior to lentivirus transduction (preferably late afternoon), prepare two wells of a 6-well plate containing 100,000 cells per well of each of PDAC,BxPc3, H6C7, and hFib cells. Infect one well with OSKM lentiviruses and use the second as an uninfected control.
    NOTE: Use a separate plate for each cell type.
  6. The following day, in the afternoon (approximately 24 h later), ensure that the cell confluency reaches at least 70% before proceeding to the next lentivirus infection step.

3. Lentivirus transduction of PDAC

  1. Defrost 5 mL of each lentivirus supernatant in a 37 °C virus incubator.
  2. Prepare two 15 mL tubes, each containing 2 mL of pre-warmed PDAC culture medium.
  3. To the first tube, add 6 mL of each reprogramming lentivirus (pSIN4-CMV-K2M and pSIN4-EF1a-O2S) and 12 µL of 4.5 mg/mL polybrene (final 4.5 µg/mL, see Table of Materials) and mix.
  4. To the second tube, add 2 µL of 4.5 mg/mL polybrene (final 4.5 µg/mL).
  5. Discard the medium from each well and wash once with PBS at room temperature.
  6. Add the reprogramming infection media (tube 1) to the first well.
  7. Add the mixture of tube 2 to the second well. This will be the uninfected control.
  8. Incubate the PDAC cells in a 37 °C, 5% CO2, and 5% O2 (hypoxia) incubator overnight.
  9. Next day, in the afternoon, discard the media from both wells and replace it with fresh PDAC culture medium.
  10. Incubate the cells at 37 °C, 5% CO2, and 5% O2 (hypoxia) for 48 h.

4. Lentivirus transduction of BxPc3 cells

  1. Defrost 3 mL of each lentivirus supernatant in a 37 °C virus incubator.
  2. Prepare two 15 mL tubes, each containing 2 mL of BxPc3 culture medium.
  3. To the first tube, add 3 mL of each reprogramming lentivirus (pSIN4-CMV-K2M and pSIN4-EF1a-O2S) and 6 µL of 4.5 mg/mL polybrene (final 4.5 µg/mL) and mix.
  4. To the second tube, add 2 µL of 4.5 mg/mL polybrene (final 4.5 µg/mL).
  5. Discard the medium from each well and wash once with PBS.
  6. Add the reprogramming infection media (tube 1) to the first well.
  7. Add the mixture of tube 2 to the second well. This will be the uninfected control.
  8. Incubate the infected BxPc3 cells at 37 °C virus and 5% CO2 overnight.
  9. Next day, in the afternoon, discard the media from both wells and replace it with fresh BxPc3 culture medium.
  10. Incubate the cells at 37 °C and 5% CO2 for 48 h.

5. Lentivirus transduction of H6c7 cells infection

  1. Defrost 4 mL of each lentivirus supernatant in a 37 °C virus incubator.
  2. Prepare two 15 mL tubes, each containing 2 mL H6c7 culture medium.
  3. To the first tube, add 4 mL of each reprogramming lentivirus (pSIN4-CMV-K2M and pSIN4-EF1a-O2S) and 8 µL of 4.5 mg/mL polybrene (final 4.5 µg/mL) and mix.
  4. To the second tube, add 2 µL of 4.5 mg/mL polybrene (final 4.5 µg/mL).
  5. Discard the medium from both wells and wash once with PBS.
  6. Add the reprogramming infection media (tube 1) to the first well.
  7. Add the mixture of tube 2 to the second well. This will be the uninfected control.
  8. Incubate the infected H6C7 cells at 37 °C virus and 5% CO2 overnight.
  9. Next day, in the afternoon, discard the media from both wells and replace them with a fresh H6c7 culture medium.
  10. Incubate the cells at 37 °C and 5% CO2 for 48 h.

6. Lentivirus transduction of hFib cells

  1. Defrost 2 mL of each lentivirus supernatant in a 37 °C virus incubator.
  2. Prepare two 15 mL tubes, each containing 2 mL hFib culture medium.
  3. To the first tube, add 2 mL of each reprogramming viruses (pSIN4-CMV-K2M and pSIN4-EF1a-O2S) and add 4 µL of 4.5 mg/mL polybrene (final 4.5 µg/mL) and mix.
  4. To the second tube, add 2 µL of 4.5 mg/mL polybrene (final 4.5 µg/mL) and mix.
  5. Discard the medium from each well and wash once with PBS.
  6. Add the reprogramming infection media (tube 1) to the first well.
  7. Add the mixture of tube 2 to the second well. This will be the uninfected control.
  8. Incubate the infected hFib cells at 37 °C and 5% CO2 overnight.
  9. Next day, in the afternoon, discard the media from both wells and replace it with fresh hFib culture medium.
  10. Incubate the cells at 37 °C and 5% CO2 for a further 48 h.
    NOTE: For efficient lentivirus transduction, titer the amount of lentivirus carefully, as this varies greatly between the different cell types. Multiple lentivirus transductions may be required for some cell types. PDAC cell lines require up to three doses, whereas one dose was enough for reprogramming BxPc3, H6C7, and hFib lines.

7. Preparation of iMEF feeder cells

  1. Prepare 40 mL 0.2% gelatine solution by diluting 1% gelatine stock solution with PBS.
  2. Coat four 6-well plates by covering each well with 2 mL of 0.2% gelatine solution.
  3. Incubate the gelatine-coated plates at 37 °C and 5% CO2 for at least 30 min.
  4. Aspirate the excess gelatine solution and leave the plates to dry under the flow hood.
  5. Thaw two vials (~ 4 million cells per vial) of irradiated mouse embryonic fibroblast (iMEFs) by swirling it in a 37 °C water bath.
    NOTE: To reduce the possibility of contamination, be careful to prevent water from splashing near the cap opening. Dry the vial with a paper towel and spray it with 70% ethanol.
  6. In the tissue culture hood, pipette the content of each thawed iMEFs vial into one 15 mL tube containing 10 mL of pre-warmed hFib culture medium in a dropwise fashion and mix well by gently inverting the tube.
  7. Spin down the cell suspension at 309 x g for 3 min at room temperature and remove the supernatant from each tube. Resuspend each cell pellet in 12 mL hFib medium.
  8. Plate 2 mL of the cell suspension per well of the gelatine-coated 6-well plates. Evenly distribute the cells by gently shaking the plates in all directions.
  9. Incubate the plates at 37 °C and 5% CO2 overnight.
    NOTE: Prepare fresh iMEF plates 24 h before being used for the reprogramming experiment.

8. Transferring the infected cells onto the iMEF feeder layer

  1. Discard media from the infected and non-infected PDAC, BxPc3, H6c7, and hFib cells. Wash each well twice with PBS at room temperature.
  2. Dissociate the cells from the plate by adding 0.5 mL of trypsin to each well. Incubate PDAC cells in a 37 °C, 5% CO2, and 5% O2 (hypoxia) incubator for 15 min.
  3. Incubate BxPc3 cells at 37 °C and 5% CO2 for 5 min.
  4. Incubate H6c7 and hFib cells at 37 °C and 5% CO2 for 4 min.
  5. Transfer the dissociated cell suspension from each well into 15 mL tubes labeled accordingly as infected or uninfected.
  6. Harvest the cells by centrifugation as follows: for PDAC, spin the cell suspension at 300 x g for 5 min; for BxPc3, spin the cell suspension at 120 x g for 5 min; for H6C7, spin the cell suspension at 112 x g for 4 mins; for hFib, spin the cell suspension at 161 x g for 3 min. Perform all the centrifugations at room temperature.
  7. Resuspend each cell type pellet in 1 mL of the appropriate culture media.
  8. Wash iMEF plates prepared in step 7 with each cell type culture media twice. i.e., wash one plate with PDAC media, one with BxPc3 media, one with H6C7 medium, and the other with hFib medium.
  9. Plate 50,000 infected cells per well in five wells of iMEF 6-well plate. Plate 50,000 uninfected control cells in the remaining one well of iMEF 6-well plate.
    NOTE: Optimise the number of infected cells to be plated from 1,000 to 50,000 cells per well.
  10. Incubate PDAC cells at 37 °C, 5% CO2, and 5% O2 (hypoxia) overnight.
  11. Incubate BxPc3, H6C7, and hFib cells at 37 °C and 5% CO2 overnight.
  12. Next day, prepare reprogramming medium as follows: add 100 mL knockout serum replacement (25% final), 5 mL of 200 mM glutamine (1 mM final), 5 mL of 100x non-essential amino acids (100 µM final), 1.5 mL of Beta-mercaptoethanol (0.1 mM final) to 400 mL Modified Eagle Medium (DMEM).
  13. Store the reprogramming media in 100 mL aliquots at 4 °C for up to 4 weeks or at -20 °C for longer.
  14. When ready to use, add 100 µL of 10 mg/mL basic fibroblast growth factor (bFGF) (10 ng/mL final) to one 100 mL reprogramming media aliquot.
  15. Warm the reprogramming media in a 37 °C water bath.
  16. Wash the cells growing on iMEFs feeders with pre-warmed reprogramming media twice.
    Add 2 mL of reprogramming medium to each well.
  17. Transfer the reprogramming plates into a 37 °C, 5% CO2and 3% O2 (hypoxia) incubator.
    NOTE: The day when reprogramming media is added is considered day 1 of reprogramming.
  18. Feed the cells daily with fresh reprogramming media until iPSC colonies start to appear.
    NOTE: Identify iPSC colonies by their ESC-like morphology (compact colonies with well-defined edges and comprised of cells with a high nucleus/cytoplasm ratio).
  19. Monitor the iPSC colonies daily, and after an adequate number have been formed, passage them as a pool.
    NOTE: Ensure that the iPSC colonies do not touch each other, as this would result in differentiation and affect their long-term stability.
  20. To establish clonal lines, passage the iPSC pool about 5 times, then pick robust colonies that maintain their ESC-like morphology.
  21. To identify fully reprogrammed iPSC colonies, carry out live staining with TRA-160 (see Table of Materials), and harvest RNA from iPSC colonies for gene expression characterization.

9. Passaging of iPSC colonies

  1. Prepare enough iMEF feeder plates 24 h before passaging the iPSC colonies as described in step 7.
  2. Wash iMEF feeder plates twice with pre-warmed reprogramming media.
  3. Add 2 mL of reprogramming media supplemented with ROCK inhibitor (Y2) (10 µM) to each well of iMEF plate.
  4. Incubate the iMEF plates in a 37 °C, 5% CO2, and 3% O2 incubator until ready to use.
  5. Prepare Ethylenediaminetetraacetic acid/ Phosphate Buffered Saline (EDTA/PBS) solution by diluting 0.5 M EDTA 1:1000 in PBS (0.5 mM final).
  6. Replace the reprogramming culture media with 0.5 mL of EDTA/PBS in each well.
  7. Incubate in a 37 °C, 5% CO2, and 3% O2 incubator or at room temperature, depending on the cell type. BxPc3 and PDAC iPSCs require 15 min incubation at 37 °C. H6C7 and hFib iPSCs need to be incubated at room temperature for 5 min.
  8. Check the iPSCs cells under the microscope until they begin to uniformly dissociate from the feeder layer throughout the entire colony.
  9. Collect the dissociated iPSC cell suspension into a 15 mL centrifuge tube. Spin down at 300 x g for 5 min at room temperature.
  10. Resuspend the cell pellet in 1 mL of reprogramming media supplemented with Y2 (10 µM).
  11. Plate the cells on iMEF feeder layer by transferring each 1 mL of iPSC cell suspension to three wells of the iMEF plate.
    NOTE: The split ratio may vary depending on the number of harvested iPSC colonies.
  12. Incubate in a 37 °C, 5% CO2 and 3% O2 incubator.

10. Live staining of iPSC colonies with TRA-1-60

  1. Prepare 0.5 mL per well of 4 µg/mL TRA-1-60 antibody in reprogramming media.
  2. Discard reprogramming media and replace it with 0.5 mL antibody mixture in each well. Incubate in a 37 °C, 5% CO2, and 3% O2 incubator for 30 min.
  3. Wash the cells twice with the reprogramming media.
  4. Capture fluorescence images with a cell imaging system using the GFP filter.
  5. Check the image quality by considering the negative control channel.

Results

Representative images displaying the morphology of iPSC colonies derived from PDAC, BXPc3, H6C7, and hFib cells are shown in Figure 1. PDAC-iPSC colonies started to form on Day 25 of reprogramming. Robust iPSC colonies with a more established ESC-like morphology were identified on Day 40 of reprogramming (Figure 1). Similarly, the formation of BxPc3-iPSCs began on Day 23 and became more established by Day 35. H6C7-iPSC formation was similar to PDAC-iPSCs and started to become established on Day 45. hFib-iPSC colonies began to form on Day 15 of reprogramming.

Stem cell reprogramming, microscopic images, depicts iPSCs at various stages, cellular morphology.
Figure 1: Representative images of iPSC colonies. The images show established hESC-like morphology derived from (A) PDAC, (B) BxPc3, (C) H6c7, and (D) hFib. The days of reprogramming are indicated above each image. Scale bars = 100 µm. Please click here to view a larger version of this figure.

Clonal iPSC lines were established from each reprogramming of PDAC, BxPc3, H6C7, and hFib cells. All established iPSC lines stained positive for TRA-1-60, an undifferentiated hESC cell surface marker, confirming their reprogramming to pluripotency (Figure 2).

Induced pluripotent stem cell differentiation, TRA-160 marker, microscopy image, cellular analysis.
Figure 2: Representative images of clonal iPSC lines. The images are derived from (A) PDAC, (B) BxPc3, (C) H6c7, and (D) hFib showing ESC-like morphology (top panels) and positive staining for TRA-1-60 (bottom panel). Scale bars = 100 µm. Please click here to view a larger version of this figure.

Discussion

To facilitate the use of iPSC reprogramming for studying cancer progression, a robust protocol has been established for reprogramming pancreatic cancer cells. Reprogramming cancer cells into pluripotency has proven to be very challenging thus far, as only a few studies have successfully generated iPSCs from cancer cells32,36,37,38,39,40,41,42,43,44,45,46. Most of these studies used immortalized cancer cell lines to generate iPSC lines, not primary patient-derived cells36,37,38,40,42,43,44,46. For instance, reprogramming four different liver cancer cell lines was attempted using the retroviral introduction of OSKM factors, but only a single cell line was successfully reprogrammed41. However, the generated liver cancer iPSC line showed a loss of stemness after a few passages, highlighting the high resistance of cancer cells to OSKM reprogramming41. Previously, attempts were made to reprogram PDAC cells using lentiviral delivery of OSKM individually; however, only a single iPSC line was generated, dependent on exogenous OSKM expression and therefore not fully reprogrammed37. Another study used episomal vectors to deliver OSKM factors without genomic integration but only managed to generate a single iPSC clone from PDAC39. The limited success in reprogramming cancer cells adds to the many challenges hampering the use of iPSC technology in cancer research.

Here, the generation of iPSCs from primary PDAC samples derived from two different patients and one established PDAC cell line (BxPc3) is explained. Moreover, iPSCs have also been generated from H6c7, a pancreatic ductal epithelial cell line. To our knowledge, this is the first report of successfully derived stable iPSC lines from BxPc3 and H6c7. Following this protocol, iPSCs have also been successfully generated from primary human fibroblasts derived from healthy individuals, expanding the applicability of the method beyond cancer research.

One of the key elements behind the success of the protocol is the use of bicistronic lentiviral vectors to co-express OS and KM factors. These vectors contain the internal ribosome entry site 2 (IRES2) to express OCT4 and SOX2 in one vector and KLF4 and cMYC in the other. Multiple studies using monocistronic vectors where each reprogramming factor was delivered individually have shown that the uptake of each vector is different, affecting OSKM stoichiometry and reprogramming efficiency47. Using bicistronic vectors can help mitigate this issue. Moreover, using IRES in lentiviral vectors has shown a significant increase in reprogramming efficiency48. In this lentivirus system, OS expression is driven by the EF1a promoter, while KM expression is under the control of a CMV promoter. It is known that the CMV promoter can be subjected to highly efficient silencing by DNA methylation and histone deacetylation, unlike EF1a49,50. Therefore, the early silencing of KM before OS during reprogramming may be a key factor for the success of the protocol. This is consistent with previous studies showing the importance of OSKM expression dynamics during reprogramming51,52,53,54,55. Thus, the bicistronic vector is also more advantageous than the polycistronic vector, where all OSKM factors are expressed from a single promoter56. Other factors that contribute to the success of the protocol include the doses of lentivirus infection and the number of infected cells used for reprogramming, which were customized for each cell type.

In summary, an optimized method for reprogramming primary PDAC cells along with other cell lines and normal cells is presented. This method will help expand the use of iPSC reprogramming to model cancer progression and, in this case, discover early PDAC biomarkers.

Disclosures

The authors declare no conflict of interest.

Acknowledgements

A.S and J.K would like to thank Cancer Research UK and OHSU for funding (CRUK-OHSU Project Award C65925/A26986). A.S is supported by an MRC career development award (MR/N024028/1). A.A is funded by a Ph.D. scholarship (Scholarship ref. 1078107040) from King Abdulaziz City for Science and Technology. J.K is funded by MRF New Investigator Grant (GCNCR1042A) and Knight CEDAR grant (68182-933-000, 68182-939-000). We thank Prof Keisuke Kaji for kindly providing the reprogramming vector pSIN4-EF1a-O2S and pSIN4-CMV-K2M. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
2-Mercaptoethanol (50 mM)Thermo Fisher31350010
Alexa Fluor 488 anti- human TRA-1-60-RBioLegend330613
Bovine Pituitary Extract (BPE)Thermo Fisher13028014
BxPc3ATCCCRL-1687
Cholera Toxin from Vibrio choleraeMerck C8052-1MG
Collagen, Type I solution from rat tailMerck C3867
Completed Defined K-SFMThermo Fisher 10744-019
Corning Costar TC-Treated Multiple Well PlatesMerck CLS3516
Corning syringe filtersMerck CLS431231
Corning tissue-culture treated culture dishesMerck CLS430599
Day Impex Virkon Disinfectant Virucidal TabletsThermo Fisher12328667
Dulbecco′s Phosphate Buffered Saline (PBS)Merck D8537
Fetal Calf Serum (FCS) Thermo Fisher10270-106
Fugene HD Transfection Reagent Promega  E2312
Gelatin solution, Type B, 2% in H2OMerck G1393-100ML
Glasgow Minimum Essential Media (GMEM)Merck G5154
Human EGF Recombinant ProteinThermo FisherPHG0311
Human FGF-basic (FGF-2/bFGF) (154 aa) Recombinant Protein, PeproTechThermo Fisher100-18B
Human Pancreatic Duct Epithelial Cell Line (H6c7)KerafastECA001-FP
iMEF feeder cells iXcells Biotechnologies10MU-001-1V
Keratinocyte Serum Free Media (KSFM) Thermo Fisher17005-042
KnockOut DMEM Thermo Fisher10829018
KnockOut serum Replacement Thermo Fisher10828028
L-Glutamine (200 mM)Thermo Fisher25030-024
MEM Non-Essential Amino Acids Solution (100x)Thermo Fisher11140050
Millex-HP 0.45 μM syringe Filter Unit (Sterile)Merck SLHP033RS
Opti-MEM Reduced Serum Medium Thermo Fisher31985062
pMDG AddGene187440
Polybrene (Hexadimethrine bromide) Merck H9268-5G
pSIN4-CMV-K2M AddGene21164
pSIN4-EF2-O2S AddGene21162
psPAX2AddGene12260
pWPT-GFP AddGene12255
RPMI 1640 Medium (ATCC modification)Thermo FisherA1049101
Sodym PyruvateThermo Fisher11360-039
Sterile Syringes for Single Use (60 mL) Thermo Fisher15899152
TrypLE Express Enzyme (1x), phenol redThermo Fisher12605036
UltraPure 0.5M EDTA, pH 8.0Thermo Fisher15575020
Y-27632 (Dihydrochloride)STEMCELL Technologies72304

References

  1. Rahib, L., et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research. 74 (11), 2913-2921 (2014).
  2. Hu, J. X., et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World Journal of Gastroenterology. 27 (27), 4298(2021).
  3. Howlader, N., et al. SEER cancer statistics review, 1975-2013. National Cancer Institute. 19, Bethesda, MD. (2016).
  4. Bengtsson, A., Andersson, R., Ansari, D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Scientific Reports. 10 (1), 16425(2020).
  5. He, J., et al. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. HPB. 16 (1), 83-90 (2014).
  6. Dusch, N., et al. Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. Journal of Gastrointestinal Surgery. 18 (4), 674-681 (2014).
  7. Principe, D. R., et al. The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy. Frontiers in Oncology. 11, 688377(2021).
  8. Papademetrio, D. L., et al. Interplay between autophagy and apoptosis in pancreatic tumors in response to gemcitabine. Targeted Oncology. 9 (2), 123-134 (2014).
  9. Ng, S. S., Tsao, M. S., Nicklee, T., Hedley, D. W. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma 1 supported by the National Cancer Institute of Canada and the Pat Myhal Fund for Pancreatic Cancer Research. Molecular Cancer Therapeutics. 1 (10), 777-783 (2002).
  10. Sultana, A., et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. Journal of Clinical Oncology. 25 (18), 2607-2615 (2007).
  11. Sun, J., Russell, C. C., Scarlett, C. J., McCluskey, A. Small molecule inhibitors in pancreatic cancer. RSC Medicinal Chemistry. 11 (2), 164-183 (2020).
  12. Jiang, H., et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nature Medicine. 22 (8), 851-860 (2016).
  13. Hruban, R. H., et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. The American Journal of Surgical Pathology. 25 (5), 579-586 (2001).
  14. Maitra, A., Hruban, R. H. Pancreatic cancer. Annual Review of Pathology: Mechanisms of Disease. 3, 157-188 (2008).
  15. Vincent, A., Herman, J., Schulick, R., Hruban, R. H., Goggins, M. Pancreatic cancer. The Lancet. 378 (9791), 607-620 (2011).
  16. Yachida, S., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 467 (7319), 1114-1117 (2010).
  17. Lennon, A. M., et al. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia. Cancer Research. 74 (13), 3381-3389 (2014).
  18. Rubio-Viqueira, B., et al. An in vivo platform for translational drug development in pancreatic cancer. Clinical Cancer Research. 12 (15), 4652-4661 (2006).
  19. Li, C., et al. Identification of pancreatic cancer stem cells. Cancer Research. 67 (3), 1030-1037 (2007).
  20. Hermann, P. C., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 1 (3), 313-323 (2007).
  21. Boj, S. F., et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 160 (1-2), 324-338 (2015).
  22. Takahashi, K., Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126 (4), 663-676 (2006).
  23. Suvà, M. L., et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 157, 580-594 (2014).
  24. Kotini, A. G., et al. Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia. Cell Stem Cell. 20 (3), 315-328 (2017).
  25. Stricker, S. H., et al. Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes Development. 27 (6), 654-669 (2013).
  26. Chao, M. P., et al. Human AML-iPSCs reacquire leukemic properties after differentiation and model clonal variation of disease. Cell Stem Cell. 20 (3), 329-344 (2017).
  27. Aparicio, L. A., et al. Clinical implications of epithelial cell plasticity in cancer progression. Cancer letters. 366 (1), 1-10 (2015).
  28. Grimont, A., Leach, S. D., Chandwani, R. Uncertain beginnings: acinar and ductal cell plasticity in the development of pancreatic cancer. Cellular and Molecular Gastroenterology and Hepatology. 13 (2), 369-382 (2022).
  29. Greenspan, L. J., Weinstein, B. M. To be or not to be: endothelial cell plasticity in development, repair, and disease. Angiogenesis. 24 (2), 251-269 (2021).
  30. Papapetrou, E. P. Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nature Medicine. 22 (12), 1392-1401 (2016).
  31. Zhang, X., Cruz, F. D., Terry, M., Remotti, F., Matushansky, I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene. 32 (18), 2249-2260 (2013).
  32. Kim, J., et al. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Reports. 3 (6), 2088-2099 (2013).
  33. Kim, J., et al. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Science Translational Medicine. 9 (398), (2017).
  34. Susac, L., et al. Structure of a fully assembled tumor-specific T cell receptor ligated by pMHC. Cell. 185 (17), 3201-3213 (2022).
  35. Yu, J., et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 324, 797-801 (2009).
  36. Carette, J. E., et al. Generation of iPSCs from cultured human malignant cells. Blood, The Journal of the American Society of Hematology. 115 (20), 4039-4042 (2010).
  37. Choi, S. M., et al. Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Blood, The Journal of the American Society of Hematology. 118 (7), 1801-1805 (2011).
  38. Hochedlinger, K., et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes & Development. 18 (15), 1875-1885 (2004).
  39. Hu, K., et al. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood, The Journal of the American Society of Hematology. 117 (14), e109-e119 (2011).
  40. Iskender, B., Izgi, K., Canatan, H. Reprogramming bladder cancer cells for studying cancer initiation and progression. Tumor Biology. 37, 13237-13245 (2016).
  41. Khoshchehreh, R., et al. Epigenetic reprogramming of primary pancreatic cancer cells counteracts their in vivo tumourigenicity. Oncogene. 38 (34), 6226-6239 (2019).
  42. Kim, H. J., et al. Establishment of hepatocellular cancer induced pluripotent stem cells using a reprogramming technique. Gut and Liver. 11 (2), 261(2017).
  43. Lin, S. L., et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA. 14 (10), 2115-2124 (2008).
  44. Miyoshi, N., et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proceedings of the National Academy of Sciences. 107 (1), 40-45 (2010).
  45. Singovski, G., et al. In vivo epigenetic reprogramming of primary human colon cancer cells enhances metastases. Journal of Molecular Cell Biology. 8 (2), 157-173 (2016).
  46. Zhao, H., et al. A highly optimized protocol for reprogramming cancer cells to pluripotency using nonviral plasmid vectors. Cellular Reprogramming (Formerly" Cloning and Stem Cells". 17 (1), 7-18 (2015).
  47. Lo, C. A., et al. Quantification of protein levels in single living cells). Cell Reports. 13 (11), 2634-2644 (2015).
  48. Yu, J., et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 324 (5928), 797-801 (2009).
  49. Prösch, S., et al. Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biological Chemistry Hoppe-Seyler. 377 (3), 195-201 (1996).
  50. Mehta, A. K., Majumdar, S. S., Alam, P., Gulati, N., Brahmachari, V. Epigenetic regulation of cytomegalovirus major immediate-early promoter activity in transgenic mice. Gene. 428 (1-2), 20-24 (2009).
  51. Chen, X., et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell. 133 (6), 1106-1117 (2008).
  52. Kim, J., Chu, J., Shen, X., Wang, J., Orkin, S. H. An extended transcriptional network for pluripotency of embryonic stem cells. Cell. 132 (6), 1049-1061 (2008).
  53. Chronis, C., et al. Cooperative binding of transcription factors orchestrates reprogramming. Cell. 168 (3), 442-459 (2017).
  54. Li, D., et al. Chromatin accessibility dynamics during iPSC reprogramming. Cell Stem Cell. 21 (6), 819-833 (2017).
  55. Soufi, A., Donahue, G., Zaret, K. S. Facilitators and impediments of the pluripotency reprogramming factors' initial engagement with the genome. Cell. 151 (5), 994-1004 (2012).
  56. Carey, B. W., et al. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proceedings of the National Academy of Sciences of the United States of America. 106, 157-162 (2009).

Reprints and Permissions

Tags

Induced Pluripotent Stem CellsPDAC ReprogrammingPluripotency InductionLentiviral TransductionEarly Diagnostic MarkersPanIN ProgressionCell Fate ConversionCancer Cell PlasticityTRA-160 Staining
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Contact Us
Recommend to Library

Privacy

Terms of Use

Policies

Copyright © 2026 MyJoVE Corporation. All rights reserved.